NEULANDLAB2021-01-012021-03-31in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2021-01-012021-03-31in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2021-01-012021-03-31in-bse-fin:FourOperatingExpenses01Member NEULANDLAB2021-01-012021-03-31in-bse-fin:FourOperatingExpenses02Member NEULANDLAB2021-01-012021-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2021-01-012021-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2021-01-012021-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2021-01-012021-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2021-01-012021-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member NEULANDLAB2021-01-012021-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares NEULANDLAB 2020-04-01 2021-03-31 2021-04-27 INR Lakhs Yearly true Cash Flow Indirect Single segment Manufacturing of Active Pharmaceutical Ingredients 2021-01-01 2021-03-31 Audited Consolidated 2447047000.00 145965000.00 2593012000.00 1191863000.00 0.00 -104023000.00 434241000.00 45779000.00 111421000.00 669830000.00 2349111000.00 243901000.00 0.00 243901000.00 47490000.00 23485000.00 70975000.00 0.00 172926000.00 0.00 0.00 0.00 0.00 172926000.00 -14833000.00 158093000.00 0.00 0.00 129005000.00 10 13.48 13.48 0.00 0.00 13.48 13.48 1 The financial results for the quarter and year ended 31 March 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 May 2021. 2 The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3 The Consolidated Financial Results include results of the following wholly owned subsidiaries: (a) Neuland Laboratories Inc., USA; (b) Neuland Laboratories KK., Japan. 4 The operations of the Company and its subsidiaries are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments . 5 Other income includes an amount of Rs. 1309 lacs towards profit on sale of 120,000 Sq. ft. of investment property situated at Nanakramguda, Hyderabad as per the Joint Development Agreement (JDA) and Supplementary Development Agreement (“SDA”) and Addendum to the SDA (collectively referred as ‘Arrangement’) entered with the Developer and its nominees for development of IT Park. 6 Other expenses for the quarter and year ended March 31, 2021 include an amount of Rs. 955 lacs towards settlement of income tax litigation under Vivad Se Vishwas Scheme 7 The Group continues to evaluate the impact of the pandemic on all aspects of its business, including impact on customers, employees, vendors and business partners. The Group has taken several business continuity measures including transport for factory employees, work from home, following the social distancing norms.The Group has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter and year ended 31 March 2021. Based on the assessment done by the management, there is no significant/material impact of COVID-19 on the results for the quarter and year ended 31 March 2021. The Group has been closely monitoring any material changes to future economic conditions. 8 The EPS for quarters has not been annualised. 9 The figures for the quarter ended 31st March, 2021 and 31st March, 2020 are the balancing figures between the audited figures in respect of the full financial year and the published figures upto nine months of the relevant financial year. 10 The Board has recommended payment of final dividend of Rs.3/-(30%) per equity share on a face value of Rs.10 each, subject to the approval of members of the Company. 11 The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period. Single segment 2020-04-01 2021-03-31 Audited Consolidated 9369131000.00 160951000.00 9530082000.00 4396570000.00 0.00 -12445000.00 1497367000.00 178983000.00 396826000.00 2019446000.00 8476747000.00 1053335000.00 0.00 1053335000.00 125573000.00 121455000.00 247028000.00 0.00 806307000.00 0.00 0.00 0.00 0.00 806307000.00 -15647000.00 790660000.00 0.00 0.00 129005000.00 10 7727183000.00 62.85 62.85 0.00 0.00 62.85 62.85 Manufactuting Expenses 347903000.00 Other expenses 321927000.00 Manufactuting Expenses 1202858000.00 Other expenses 816588000.00 178983000.00 -280603000.00 -300750000.00 0.00 -89766000.00 0.00 0.00 32792000.00 0.00 366455000.00 0.00 461715000.00 0.00 396826000.00 0.00 -12583000.00 0.00 302322000.00 0.00 -14780000.00 0.00 16675000.00 0.00 0.00 0.00 -130925000.00 0.00 0.00 0.00 893011000.00 1946346000.00 0.00 0.00 0.00 52729000.00 0.00 1893617000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 85000.00 1053970000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21514000.00 0.00 188134000.00 0.00 -844237000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 363646000.00 1260275000.00 35155000.00 0.00 25660000.00 179160000.00 0.00 0.00 -1136604000.00 -87224000.00 0.00 -87224000.00 0.00 -87224000.00